Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Buy" from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been given a consensus recommendation of "Buy" by the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $66.17.

Several analysts have recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Jefferies Financial Group lifted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. HC Wainwright upgraded Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target on the stock in a research note on Tuesday. Finally, Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th.

Insider Activity

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 7,131 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the sale, the chief executive officer now directly owns 70,720 shares of the company's stock, valued at approximately $3,273,628.80. The trade was a 9.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 2,137 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the transaction, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. This represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock worth $1,581,173 over the last three months. 8.25% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TARS. Summit Investment Advisors Inc. lifted its position in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares during the period. Amalgamated Bank increased its stake in shares of Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after acquiring an additional 295 shares during the last quarter. Sherbrooke Park Advisers LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 7.2% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company's stock worth $364,000 after acquiring an additional 443 shares during the period. Crowley Wealth Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $25,000. Finally, Arizona State Retirement System boosted its position in shares of Tarsus Pharmaceuticals by 6.1% in the first quarter. Arizona State Retirement System now owns 8,182 shares of the company's stock worth $420,000 after acquiring an additional 470 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Up 0.4%

Shares of Tarsus Pharmaceuticals stock traded up $0.17 on Friday, reaching $42.05. 748,538 shares of the company were exchanged, compared to its average volume of 702,651. The stock's 50 day moving average price is $47.28 and its 200-day moving average price is $48.99. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a market cap of $1.77 billion, a P/E ratio of -11.04 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, equities analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.